Staff Report

Teleflex (Wayne, Pennsylvania), a provider of medical devices for critical care and surgery, reported results of a new peer-reviewed study involving the Arrow PICC with Chlorag+ard Technology, published in the fall 2014 issue of the Journal of the Association for Vascular Access. The Arrow PICC with Chlorag+ard Technology is an antimicrobial and antithrombogenic PICC.

The research, using the Arrow PICC with Chlorag+ard Technology, determined that this kind of Peripherally Inserted Central Catheter (PICC) was associated with a nearly nine-fold drop in the rate of Central Line-Associated Bloodstream Infections (CLABSIs). The peer-reviewed study was conducted at Sharp Chula Vista Medical Center (Chula Vista, California).

The study was undertaken in part because the medical center's CLABSI rate had remained above the national benchmark, despite comprehensive efforts to prevent these potentially deadly infections. Use of an antimicrobial catheter in such circumstances is recommended by the Centers for Disease Control and Prevention (Atlanta) and the Infusion Nurses Society (Norwood, Massachusetts).

In the study, concurrent data was collected from 260 patients who received the ARROW PICC with Chlorag+ard Technology. That data was then compared to retrospective data for 257 patients who had only received unprotected PICCs during the previous year.

In addition, a financial analysis showed that the Arrow PICC with Chlorag+ard Technology reduced costs associated with CLABSIs. Using the device enabled the hospital to avoid seven CLABSIs during the six-month study period. Conservatively assuming a treatment cost of $16,500 per infection, researchers calculated that SCVMC saved $115,500 during the study period – an amount that includes the added cost for the preventive PICCs. The study author was Glenell Rutkoff, manager ambulatory and ancillary services at SCVMC.

"We are excited about the results of this important study," said Jay White, president, Vascular Division of Teleflex. "It is well supported in the literature that PICC-related infections among inpatient populations are similar to those of acute non-medicated (non-tunneled) CVCs and higher than those of acute medicated (non-tunneled) CVCs. Also, for patients in the ICU, the risk of PICC-related infections can be nearly double that of patients outside of the ICU. In this era of healthcare reform, we know hospitals are looking for solutions to reduce CLABSI rates. For all these reasons, we are pleased to provide hospitals with Chlorag+ard Technology in an effort to reduce PICC-related infections, improve hospital efficiencies and overall costs. This, coupled with the fact that Chlorag+ard Technology also provides antithrombogenic benefits, allow us to provide solutions to multiple complications associated with PICCs."

Recently, Teleflex has been making med-tech headlines through funding initiatives and significant partnerships.

In May, the company priced its offering of $250 million aggregate principal amount of 5.25% senior notes due 2024 at an issue price of 100% in a private placement. Teleflex said it intended to use the net proceeds from the offering to repay about $245 million of borrowings under its revolving credit facility.

In April, the company made waves when it partnered with Intuitive Surgical (Sunnyvale, California) to manufacture the Weck disposable trocar seals and obturators for the new da Vinci Xi Surgical System. The partnership provided surgeons performing robotic procedures with an access solution that offers the same level of confidence, clarity, and control as Teleflex's Weck Vista Bladeless Laparoscopic Access Ports, used in standard laparoscopic cases.

The Weck brand seals and trocars developed for the da Vinci Xi System use the same technology as Weck Vista Access Ports, specifically the patented atraumatic dilating obturator tip.

No Comments